Evidence map›Paper›PMID 30214181›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2018

COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan.

Ataru Igarashi, Yoshinosuke Fukuchi, Kazuto Hirata, Masakazu Ichinose, Atsushi Nagai, Masaharu Nishimura, Hajime Yoshisue, Kenichi Ohara, Jean-Bernard Gruenberger

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Narrative review of current COPD status in Japan.Journal of thoracic disease · 2021
    Review
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Ataru IgarashiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, atarui1@mac.com.
Yoshinosuke FukuchiDepartment of Respiratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Kazuto HirataDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Atsushi NagaiResearch Institute for Respiratory Diseases, Shin-Yurigaoka General Hospital, Kawasaki City, Japan.
Masaharu NishimuraDepartment of Pulmonary Medicine, Faculty School of Medicine, Hokkaido University, Hokkaido, Japan.
Hajime YoshisueMedical Division, Novartis Pharma K.K., Tokyo, Japan.
Kenichi OharaMarket Access Division, Novartis Pharma K.K., Tokyo, Japan.
Jean-Bernard GruenbergerMarket Access Division, Novartis Pharma AG, Basel, Switzerland.
Novartis (Japan) · JPHokkaido University of Science · JPJuntendo University · JPKawasaki Hospital · JPNovartis (Switzerland) · CHOsaka City University · JPThe University of Tokyo · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COPD remains a major health problem in Japan. Patients with COPD experience a reduced quality of life (QoL) and have a higher chance of work impairment and productivity loss. However, there is a lack of data on the impact of COPD in terms of QoL and work activity impairment in Japan. This study assessed the socioeconomic burden of COPD in Japan and the impact it may have on the working age population. Patients and methods: This was a 2-year retrospective chart review in COPD patients aged ≥40 years, with at least one health care visit to clinic or hospital in the previous 12 months. Patients were required to have available medical charts for at least the previous 24 months. Symptoms were assessed using COPD assessment test score; EuroQoL Group 5 Dimension (EQ-5D-5L) and work productivity and activity impairment general health questionnaires were used to evaluate health-related QoL and work productivity, and health care resource utilization data were obtained from clinical charts. Results: In total, 71 patients aged <65 years, and 151 patients aged ≥65 years were included; the majority of patients had moderate or severe airflow limitation. Exacerbations (moderate or severe) were reported by ~35% of patients in both age groups; 52.1% and 62.9% of patients in the <65-year and ≥65-year age groups had COPD assessment test scores ≥10. EQ-5D-5L index scores in the <65-year and ≥65-year age groups were 0.79 and 0.77, respectively. Work productivity and activity impairment scores were higher in <65-year age group. Annual costs of health care resource use per patient in the <65-year and ≥65-year age groups were ¥438,975 (US$4,389) and ¥467,871 (US$4,678), respectively. Costs due to productivity loss were estimated to be ¥5,287,024 (US$52,870) in the <65-year age group and ¥3,018,974 (US$30,187) in the ≥65-year age group. Conclusion: COPD represents a significant socioeconomic burden in Japan. Patients with COPD report significant use of health care resources. Higher impact on work impairment and productivity loss was observed frequently in the working age population.

Indexed as

Quality of LifeSocioeconomic FactorsWork PerformanceAdultAgedCross-Sectional StudiesDisease ProgressionEfficiencyEx-SmokersFemaleHealth Care CostsHumansJapanMaleMiddle AgedPulmonary Disease, Chronic Obstructivechart reviewEQ-5D-5L questionnairehealth care resource utilizationhealth-realted quality of lifeproductivity losswork impairment WPAI-GH

Identifiers

PMID30214181
PMCPMC6118262
OpenAlexW2888984237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.